I recall the survey response was that the clinicians suspected it would’ve changed their treatment plan in about half their patients.
Logically, you would have to scan all your patients to know which half would benefit from a change to treatment plan.
If it’s as much better as indications thus far are suggesting, it will dominate the market, not just slot in (TLX investor since pre-IPO btw)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.01 |
Change
-0.070(3.37%) |
Mkt cap ! $645.9M | |||
| Open | High | Low | Value | Volume |
| $2.06 | $2.06 | $1.97 | $4.379M | 2.177M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $2.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.03 | 1387 | 1 |
View Market Depth
| Last trade - 16.11pm 23/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |